Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 09/23 05:35:07 pm
68.45 EUR   -0.70%
09/21 SANOFI : Files Suit in U.S. to Defend Patent Rights on Lantus and La..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/20 SANOFI : Files Suit in U.S. to Defend Patent Rightson Lantus and Lan..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/21 SANOFI : Files Suit in U.S. to Defend Patent Rights on Lantus and Lantus Solosta..
09/21DJMylan CEO Faces Tough Questioning in EpiPen Hearing
09/21 Indian pharma firms in global alliance to fight drug resistance
09/20 SANOFI : Losing steam in the war vs dengue
09/20 SANOFI : Files Suit in U.S. to Defend Patent Rightson Lantus and Lantus Solostar
09/20DJBusiness Watch -- WSJ
09/19 SANOFI : Treatment Effects Maintained Over Six Years in Patients with Relapsing ..
09/19DJSANOFI : Files Suit Against Merck, Claiming Patent Infringements -Update
09/19DJSanofi Files Suit Against Merck
09/19DJSANOFI : Files Suit Against Merck on Patent Infringements -Update
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/24 BIOTECH : What's Next For M&A?
09/23 Priority Review Vouchers Revisited
09/23 BIOTECH FORUM DAILY DIGEST : Can Biotech Broach Resistance Levels? Worst Now Ove..
09/22 Biontech Deal Sees Roche Bet On mRNA
09/22 In Teva, Regeneron Finds Its Sanofi For Pain
Advertisement
Financials (€)
Sales 2016 36 923 M
EBIT 2016 9 287 M
Net income 2016 5 275 M
Debt 2016 5 441 M
Yield 2016 4,30%
P/E ratio 2016 15,70
P/E ratio 2017 14,39
EV / Sales 2016 2,54x
EV / Sales 2017 2,54x
Capitalization 88 235 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 82,8 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-12.91%99 053
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results